Fusion Pharmaceuticals Inc.

NasdaqGS:FUSN Stok Raporu

Piyasa değeri: US$1.8b

Fusion Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Fusion Pharmaceuticals CEO'su John Valliant, Dec2014 tarihinde atandı, in görev süresi 9.5 yıldır. in toplam yıllık tazminatı $ 2.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 28.7% maaş ve 71.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.37% ine doğrudan sahiptir ve bu hisseler $ 6.86M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 5.2 yıldır.

Anahtar bilgiler

John Valliant

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi28.7%
CEO görev süresi9.5yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi2.8yrs
Yönetim Kurulu ortalama görev süresi5.2yrs

Son yönetim güncellemeleri

Recent updates

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Mar 03

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Jan 30
Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Sep 16

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Aug 29

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10
Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Aug 09

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Jun 23

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28
We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Fusion Pharma trades higher on early-stage data for cancer therapy

Jun 14

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Mar 01
How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Jan 25
Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Fusion Pharmaceuticals EPS misses by $0.04

Nov 10

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Nov 02

CEO Tazminat Analizi

John Valliant'un ücretlendirmesi Fusion Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2024n/an/a

-US$104m

Dec 31 2023US$2mUS$597k

-US$95m

Sep 30 2023n/an/a

-US$91m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$92m

Dec 31 2022US$3mUS$595k

-US$88m

Sep 30 2022n/an/a

-US$80m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$3mUS$597k

-US$81m

Sep 30 2021n/an/a

-US$77m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$86m

Dec 31 2020US$7mUS$505k

-US$80m

Sep 30 2020n/an/a

-US$75m

Jun 30 2020n/an/a

-US$65m

Mar 31 2020n/an/a

-US$24m

Dec 31 2019US$1mUS$399k

-US$16m

Tazminat ve Piyasa: John 'nin toplam tazminatı ($USD 2.08M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.57M ).

Tazminat ve Kazançlar: John 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

John Valliant (53 yo)

9.5yrs

Görev süresi

US$2,081,586

Tazminat

Dr. John F. Valliant Ph D, is Founder of Fusion Pharmaceuticals Inc. and its Chief Executive Officer & Director since December 2014. He served as Member of Scientific Advisory Board of Molecular Insight Ph...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
John Valliant
Founder9.5yrsUS$2.08m0.37%
$ 6.9m
Mohit Rawat
President & Chief Business Officer2.8yrsUS$1.41m0.015%
$ 276.8k
John Crowley
CFO & Compliance Officer5.3yrsUS$1.30m0.012%
$ 224.4k
Eric Burak
Chief Technology Officer2.6yrsUS$1.42m0.045%
$ 829.5k
Christopher Leamon
Chief Scientific Officer2.6yrsVeri yok0.014%
$ 257.7k
Amanda Cray
Senior Director of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Maria Stahl
Chief Legal Officer3.8yrsVeri yokVeri yok
Eric Hoffman
Senior Vice President of Business Development2.8yrsVeri yokVeri yok
Cara Ferreira
Chief of Staffno dataVeri yokVeri yok
Joanne Schindler
Executive Vice President of Medical Director & Clinical Development2.2yrsVeri yokVeri yok
Dmitri Bobilev
Chief Medical Officer1.6yrsVeri yokVeri yok

2.8yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim: FUSN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
John Valliant
Founder9.5yrsUS$2.08m0.37%
$ 6.9m
Barbara Duncan
Independent Chairperson of the Board3.7yrsUS$126.49k0%
$ 0
Pablo Cagnoni
Independent Director4.5yrsUS$103.49k0%
$ 0
Steven Gannon
Independent Director4.4yrsUS$108.24k0.066%
$ 1.2m
Jeremy Bender
Independent Directorless than a yearUS$101.89k0%
$ 0
Deepak Khuntia
Member of Advisory Board5.9yrsVeri yokVeri yok
Donald Bergstrom
Independent Director3.2yrsUS$98.49k0%
$ 0
Geoffrey Shapiro
Member of Advisory Board5.9yrsVeri yokVeri yok
Rosalyn Juergens
Member of Advisory Board5.9yrsVeri yokVeri yok
Gillies O'Bryan-Tear
Member of Advisory Board5.9yrsVeri yokVeri yok
Oliver Sartor
Member of Advisory Board5.9yrsVeri yokVeri yok
Philina Lee
Independent Director3.3yrsUS$97.49k0%
$ 0

5.2yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FUSN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).